# A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer

> **NCT00190489** · PHASE3 · COMPLETED · sponsor: **Japan Clinical Oncology Group** · enrollment: 450 (—)

## Conditions studied

- Breast Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles
- **DRUG:** Docetaxel 60mg/m2 every 21 days for 6 cycles
- **DRUG:** AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles

## Key facts

- **NCT ID:** NCT00190489
- **Lead sponsor:** Japan Clinical Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-01
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 450 (—)
- **Last updated:** 2016-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190489, "A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00190489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*